Stryker Corporation

NYSE SYK

Stryker Corporation Price to Sales Ratio (P/S) on January 14, 2025: 6.29

Stryker Corporation Price to Sales Ratio (P/S) is 6.29 on January 14, 2025, a 7.88% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Stryker Corporation 52-week high Price to Sales Ratio (P/S) is 6.80 on November 29, 2024, which is 8.09% above the current Price to Sales Ratio (P/S).
  • Stryker Corporation 52-week low Price to Sales Ratio (P/S) is 5.63 on August 05, 2024, which is -10.56% below the current Price to Sales Ratio (P/S).
  • Stryker Corporation average Price to Sales Ratio (P/S) for the last 52 weeks is 6.27.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
NYSE: SYK

Stryker Corporation

CEO Mr. Kevin A. Lobo
IPO Date March 17, 1980
Location United States
Headquarters 2825 Airview Boulevard
Employees 52,000
Sector Health Care
Industries
Description

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Similar companies

DXCM

DexCom, Inc.

USD 79.17

-0.84%

EW

Edwards Lifesciences Corporation

USD 71.04

-0.07%

STE

STERIS plc

USD 207.57

0.10%

ABT

Abbott Laboratories

USD 113.02

-0.15%

MDT

Medtronic plc

USD 85.25

4.23%

ZBH

Zimmer Biomet Holdings, Inc.

USD 104.71

-0.74%

ZIMV

ZimVie Inc.

USD 13.47

-1.25%

BSX

Boston Scientific Corporation

USD 95.65

1.10%

StockViz Staff

January 15, 2025

Any question? Send us an email